NPK PHARMASOFT LLC announces the inclusion of a new indication – attention deficit hyperactivity disorder in children (aged 6 years and over), including hyperactivity, attention deficit, and impulsivity – in the instructions for medical use of the medicinal product Mexidol ® film-coated tablets, 125 mg 1,2 .
In children with hyperactivity and attention deficit, Mexidol ® helps to increase concentration and the ability to focus, increase perseverance, reduce signs of hyperactivity and decrease impulsivity, which helps to improve the learning and social adaptation of children 2 .
1Letter from the Department for Regulation of Circulation of Medicines and Medical Devices of the Ministry of Health of Russia dated 08.02.2023 No. 25-6-4236081/Izm/R/Izm.
2 Package leaflet – information for the patient (LP-No. (000086)-(RG-RU) dated October 30, 2020) — https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=bf67bb45-298d-45a0-a03a-9bbee2b1ecbc .
